<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587116</url>
  </required_header>
  <id_info>
    <org_study_id>C0371004</org_study_id>
    <secondary_id>2017-001271-23</secondary_id>
    <secondary_id>NAB PROTOCOL</secondary_id>
    <nct_id>NCT03587116</nct_id>
  </id_info>
  <brief_title>Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)</brief_title>
  <official_title>AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR nAb TO AAV VECTOR-SPARK100 AND MODERATELY SEVERE TO SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C≤1%) WHO ARE NEGATIVE FOR nAb TO AAV VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC PH 3 GENE THERAPY STUDIES (See Detailed Description Section for Official Protocol Title)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish a minimum of 6 months of prospective efficacy data of current FIX prophylaxis&#xD;
      replacement therapy in the usual care setting of hemophilia B subjects, who are negative for&#xD;
      nAb to AAV-Spark100, prior to the Phase 3 gene therapy study.&#xD;
&#xD;
      To establish a minimum of 6 months of prospective efficacy data of current FVIII prophylaxis&#xD;
      replacement therapy in the usual care setting of hemophilia A subjects, who are negative for&#xD;
      nAb to SB-525 capsid (AAV6), prior to the Phase 3 gene therapy study.&#xD;
&#xD;
      The enrollment for hemophilia A participants is completed. At this time participants are only&#xD;
      being enrolled for hemophilia B cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, MULTI-CENTER, LEAD-IN STUDY TO EVALUATE AT LEAST&#xD;
      6 MONTHS OF PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF CURRENT FACTOR IX (FIX) OR&#xD;
      FACTOR VIII (FVIII) PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY&#xD;
      SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR NEUTRALIZING&#xD;
      ANTIBODIES TO ADENO-ASSOCIATED VIRUS VECTOR-SPARK100 (BENEGENE-1) AND MODERATELY SEVERE TO&#xD;
      SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C≤1%) WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES&#xD;
      TO ADENO-ASSOCIATED VIRUS VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC&#xD;
      PHASE 3 GENE THERAPY STUDIES&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Anticipated">October 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The data obtained from this 6 month lead-in study will serve as the control group for the subsequent Phase 3 gene therapy study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized bleeding rate (ABR)</measure>
    <time_frame>6 months</time_frame>
    <description>The annualized bleeding rate (ABR) per subject will be calculated as the number of bleeds over number of days subject received FIX prophylaxis replacement therapy from baseline visit (Day 1) to end of study x 365.25 days. ABR will be summarized using descriptive statistics (n, mean, standard deviation, median, Q1, Q3, minimum, maximum).&#xD;
The annualized bleeding rate (ABR) per subject will be calculated as the number of bleeds over number of days subject received FVIII prophylaxis replacement therapy from baseline visit (Day 1) to end of study x 365.25 days. ABR will be summarized using descriptive statistics (n, mean, standard deviation, median, Q1, Q3, minimum, maximum).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>The primary safety analysis will be performed on all subjects that sign the informed consent document and are subsequently identified as nAb negative and are enrolled (complete baseline visit) into the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Events of special interest (ESI):inhibitor against FIX or FVIII, thrombotic events, and FIX or FVIII hypersensitivity reactions</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency and percentage of these ESI events will be summarized by event. In addition any events leading to discontinuation from the study will be described.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized infusion rate (AIR)</measure>
    <time_frame>6 months</time_frame>
    <description>The annualized infusion rate (AIR) per subject will be calculated as the number of infusions received over number of days subject received FIX prophylaxis replacement therapy from baseline visit (Day 1) to end of study x 365.25 days. AIR will be summarized using descriptive statistics (n, mean, standard deviation, median, Q1, Q3, minimum, maximum).&#xD;
The annualized infusion rate (AIR) per subject will be calculated as the number of infusions received over number of days subject received FVIII prophylaxis replacement therapy from baseline visit (Day 1) to end of study x 365.25 days. AIR will be summarized using descriptive statistics (n, mean, standard deviation, median, Q1, Q3, minimum, maximum).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose and total factor consumption</measure>
    <time_frame>6 months</time_frame>
    <description>The total factor IX replacement therapy consumption and the corresponding dose will be descriptively summarized by the categories of the replacement therapy, where appropriate. Infusion diary (electronic infusion diary) of the factor IX replacement therapy will be listed.&#xD;
The total factor VIII replacement therapy consumption and the corresponding dose will be descriptively summarized by the categories of the replacement therapy, where appropriate. Infusion diary (electronic infusion diary) of the factor VIII replacement therapy will be listed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding events (spontaneous and/or traumatic)</measure>
    <time_frame>6 months</time_frame>
    <description>The number of bleeding episodes will be summed up by spontaneous, traumatic and overall as defined as any bleed occurring &gt;72 hours after stopping treatment from the original bleed for which treatment was initiated or a bleed occurring at a different site from the original bleed regardless of the time from last injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hemophilia B</condition>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Standard of Care FIX replacement therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care FVIII replacement therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care FIX Replacement therapy</intervention_name>
    <description>There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.</description>
    <arm_group_label>Standard of Care FIX replacement therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care FVIII Replacement therapy</intervention_name>
    <description>There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.</description>
    <arm_group_label>Standard of Care FVIII replacement therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Hemophilia B Population:&#xD;
&#xD;
          1. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the participant or his legally authorized representative has been informed of all&#xD;
             pertinent aspects of the study.&#xD;
&#xD;
          2. Willing and able to comply with scheduled visits, FIX prophylaxis treatment plan,&#xD;
             laboratory tests and other study procedures.&#xD;
&#xD;
          3. Males ≥ 18 and &lt;65 years of age with moderately severe to severe hemophilia B and&#xD;
             documented FIX activity (≤2%) prior to baseline visit.&#xD;
&#xD;
          4. Previous experience with FIX therapy (≥50 documented exposure days to a FIX protein&#xD;
             product such as recombinant, plasma-derived or extended half-life FIX product).&#xD;
&#xD;
          5. Subjects on FIX prophylaxis replacement therapy (recombinant, plasma-derived or&#xD;
             extended half-life FIX product) must have the intention to remain on FIX prophylaxis&#xD;
             replacement therapy for the duration of the study.&#xD;
&#xD;
          6. No known hypersensitivity to FIX replacement product.&#xD;
&#xD;
          7. No history of FIX inhibitor (clinical or laboratory-based assessment) defined as a&#xD;
             titer&#xD;
&#xD;
               -  0.6 BU/mL, regardless of the laboratory normal range, or any measured Bethesda&#xD;
                  inhibitor titer greater than the upper limit of normal for the laboratory&#xD;
                  performing the assay. Clinically, no signs or symptoms of decreased response to&#xD;
                  FIX administration. Subjects will not be required to undergo diagnostic&#xD;
                  evaluation of inhibitor status to participate in the study.&#xD;
&#xD;
        Hemophilia A Population:&#xD;
&#xD;
          1. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the participant or his legally authorized representative has been informed of all&#xD;
             pertinent aspects of the study.&#xD;
&#xD;
          2. Willing and able to comply with scheduled visits, FVIII prophylaxis treatment plan,&#xD;
             laboratory tests and other study procedures.&#xD;
&#xD;
          3. Males ≥18 and &lt;65 years of age with moderately severe to severe hemophilia A and&#xD;
             documented FVIII activity (≤1%) prior to baseline visit.&#xD;
&#xD;
          4. Previous experience with FVIII therapy (≥150 documented exposure days to a FVIII&#xD;
             protein product such as recombinant, plasma-derived or extended half-life FVIII&#xD;
             product).&#xD;
&#xD;
          5. Subjects on FVIII prophylaxis replacement therapy (recombinant, plasma-derived or&#xD;
             extended half-life FVIII product) must have the intention to remain on FVIII&#xD;
             prophylaxis replacement therapy for the duration of the study.&#xD;
&#xD;
          6. No known hypersensitivity to FVIII replacement product.&#xD;
&#xD;
          7. No history of FVIII inhibitor (clinical or laboratory-based assessment) defined as a&#xD;
             titer ≥0.6 BU/mL, regardless of the laboratory normal range, or any measured Bethesda&#xD;
             inhibitor titer greater than the upper limit of normal for the laboratory performing&#xD;
             the assay. Clinically, no signs or symptoms of decreased response to FVIII&#xD;
             administration. Subjects will not be required to undergo diagnostic evaluation of&#xD;
             inhibitor status to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anti-AAV-Spark100 neutralizing antibody titer above or equal to 1:1 performed by a&#xD;
             central laboratory during screening in hemophilia B subjects or Anti- SB-525 capsid&#xD;
             (AAV6) neutralizing antibody titer (above or equal to the lowest detectable titer)&#xD;
             performed by a central laboratory during screening in hemophilia A subjects.&#xD;
&#xD;
          2. Lack of patient compliance with documentation of bleeds and/or prophylaxis replacement&#xD;
             therapy administration.&#xD;
&#xD;
          3. If there is no documentation regarding hepatitis status, as defined below, within the&#xD;
             last 12 months prior to screening for hepatitis B and 6 months prior to screening for&#xD;
             hepatitis C, then subjects will be required to have the following hepatitis testing&#xD;
             performed at screening:&#xD;
&#xD;
               1. Hepatitis B screening (acute and chronic):&#xD;
&#xD;
                  HBsAg (also referred to as Hepatitis B surface antigen), HBV-DNA viral assay&#xD;
                  (also referred to as a nucleic acid test for Hepatitis B virus DNA), and Anti-HBc&#xD;
                  (also referred to as Total Hepatitis B core antibody).&#xD;
&#xD;
                    -  A subject is not eligible if either HbsAg is positive or HBV-DNA is&#xD;
                       positive/detectable.&#xD;
&#xD;
                    -  Anti-HBc must be obtained in all subjects for determination of whether the&#xD;
                       subject had prior hepatitis B. If the anti-HBc is positive and both HBsAg&#xD;
                       and HBV DNA are negative this would be consistent with a prior infection and&#xD;
                       the subject would be eligible for the study. Anti-HBc must be obtained in&#xD;
                       all subjects to discriminate between those with no prior hepatitis B and&#xD;
                       those with prior infection in the event of reactivation. FDA has noted&#xD;
                       reactivation of hepatitis B virus exists.&#xD;
&#xD;
                    -  One documented negative HBV-DNA viral load is sufficient to assess&#xD;
                       eligibility. A subject who is currently undergoing anti-viral therapy for&#xD;
                       hepatitis B is not eligible.&#xD;
&#xD;
               2. Hepatitis C (acute or chronic):&#xD;
&#xD;
                    -  A subject who is currently undergoing anti-viral therapy for chronic&#xD;
                       hepatitis C is not eligible.&#xD;
&#xD;
                    -  Subjects treated with anti-viral therapy for chronic hepatitis C, must have&#xD;
                       completed anti-viral therapy at least 6 months prior to screening and have a&#xD;
                       negative HCV-RNA at least 6 months prior to screening.&#xD;
&#xD;
                    -  All subjects (who are not currently undergoing anti-viral therapy for&#xD;
                       chronic hepatitis C) must have a single HCV-RNA load assay (also referred to&#xD;
                       as a nucleic acid test [NAT] for HCV RNA) obtained during the 6 months&#xD;
                       preceding screening. This includes subjects with prior known chronic&#xD;
                       hepatitis C who have completed treatment with anti-viral therapy.&#xD;
&#xD;
                    -  A subject is not eligible if his HCV-RNA load assay result is&#xD;
                       positive/detectable.&#xD;
&#xD;
          4. Currently on antiviral therapy for hepatitis B or C.&#xD;
&#xD;
          5. A subject is not eligible if any of the following pre-existing diagnoses, which are&#xD;
             indicative of significant underlying liver disease, are present in the medical record:&#xD;
&#xD;
               -  Portal hypertension; or&#xD;
&#xD;
               -  Splenomegaly; or&#xD;
&#xD;
               -  Hepatic encephalopathy.&#xD;
&#xD;
             All subjects who do not have the listed pre-existing diagnoses above must have the&#xD;
             following assessments performed within the last 12 months prior to screening and if&#xD;
             not will need to be tested for liver fibrosis status at screening:&#xD;
&#xD;
               -  Measurement of serum albumin. A subject is not eligible if the serum albumin&#xD;
                  level is below the testing laboratory's lower limit of normal; and&#xD;
&#xD;
               -  One of the following diagnostic tests for liver fibrosis. The following results&#xD;
                  are indicative of fibrosis and exclude the subject from participation:&#xD;
&#xD;
               -  FibroScan, with a score &gt;8.3 kPa units;&#xD;
&#xD;
               -  FibroTest/FibroSURE with a result &gt;0.48*; or&#xD;
&#xD;
               -  AST-to-Platelet Ratio Index (APRI) &gt;1.&#xD;
&#xD;
                    -  Please note, if a subject has a known history of Gilbert's syndrome, a&#xD;
                       FibroTest cannot be used for fibrosis testing.&#xD;
&#xD;
          6. Documented serological evidence of human immunodeficiency virus HIV-1 or HIV-2 with&#xD;
             Cluster of Differentiation 4 positive (CD4+) cell count ≤200 mm3 within the last 12&#xD;
             months prior to screening. Subjects who are HIV positive and stable, have an adequate&#xD;
             CD4 count (&gt;200/mm3) and undetectable viral load (&lt;50 gc/mL) documented within the&#xD;
             preceding 12 months, and are on an antiretroviral drug regimen are eligible to enroll.&#xD;
             Subjects who have not been tested within the prior 12 months of screening will need to&#xD;
             be tested for HIV status at screening.&#xD;
&#xD;
          7. History of chronic infection or other chronic disease that the investigator deems an&#xD;
             unacceptable risk. Any patient with a history of thrombotic events including but not&#xD;
             limited to stroke or myocardial infarction.&#xD;
&#xD;
          8. Any concurrent clinically significant major disease or condition that the investigator&#xD;
             deems unsuitable for participation or other acute or chronic medical or psychiatric&#xD;
             condition including recent (within the past year) or active suicidal ideation or&#xD;
             behavior or laboratory abnormality that may increase the risk associated with study&#xD;
             participation or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the subject inappropriate for entry into this&#xD;
             study.&#xD;
&#xD;
          9. Participation in other studies if involving administration of investigational&#xD;
             product(s) within the last 3 months prior to study entry and/or during study&#xD;
             participation or in a previous gene therapy clinical study within the last 12 months&#xD;
             prior to screening.&#xD;
&#xD;
             • Participants already enrolled in this lead-in study (C0371004) may be allowed to&#xD;
             participate in the screening and baseline periods of either C0371002 or C3731003&#xD;
             protocols prior to their completion of the end of study visit in this lead-in study.&#xD;
&#xD;
         10. Any subject who previously received fidanacogene elaparvovec (SPK-9001) (hemophilia B)&#xD;
             or SB-525 (hemophilia A) or any AAV gene-based therapy.&#xD;
&#xD;
         11. Any subject with a planned surgical procedure requiring FIX (hemophilia B) or FVIII&#xD;
             (hemophilia A) surgical prophylactic factor treatment in the next 24 months.&#xD;
&#xD;
         12. Investigator site staff members directly involved in the conduct of the study and&#xD;
             their family members, site staff members otherwise supervised by the investigator, or&#xD;
             subjects who are Pfizer employees, including their family members, directly involved&#xD;
             in the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical and Translational Research Unit (CTRU)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Childrens Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco - UCSF HTC</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco - Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco - Outpatient Hematology Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Service</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia &amp; Thrombosis Center, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mississippi Center for Advanced Medicine</name>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Childhood Diseases</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn Blood Disorder Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn Comprehensive Hemophilia &amp; Thrombosis Program, Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bloodworks NW</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc/Unité d'Hématology et Hémostase</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Hemoterapia e Hematologia do Para - Fundação HEMOPA</name>
      <address>
        <city>Belem</city>
        <state>Para</state>
        <zip>66033-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>SAO Paulo</state>
        <zip>13083-878</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>lnstituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - HEMORIO</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre - Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cardiologique Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Timone - Enfants</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel-Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Necker, Hematologie Adultes</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn. Anstalt des oeffentlichen Rechts</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt, Goethe-Universitaet</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Hippokration&quot;</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;LAIKO&quot;, 2nd Regional Blood Transfusion Center</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center, The National Hemophilia Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SODc. Malattie Emorragiche e della Coagulazione Centro di Riferimento Regionale per le</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Roma &quot;La Sapienza&quot;- Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital - Transfusion Medicine</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapporo Tokushukai Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>004-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Hospital</name>
      <address>
        <city>Iruma-gun</city>
        <state>Saitama</state>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Center for Child Health and Development</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ogikubo Hospital</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <zip>167-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Center</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H.U. La Paz.</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H.U. Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Cocuk Sagligi Ve Hastaliklari Anabilim Dali Pediatric Hematoloji</name>
      <address>
        <city>Bornova</city>
        <state>İ̇zmir</state>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hematoloji BD</name>
      <address>
        <city>Bornova</city>
        <state>İ̇zmir</state>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hospital, Department of Pediatric Hematology</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Medical Faculty Hospital</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Gaziantep University Sahinbey Training and Research Hospital</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul University Oncology Institute</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Non Malignant Haematology Research Unit</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Haematology</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Saudi Arabia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C0371004</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

